Tavneos Liver Injury Update: FDA Warning and Withdrawal Proposal
The FDA warned about serious Tavneos liver injuries in 2026 and later proposed withdrawing approval. Here is what patients and families should know.
-
-
Dupixent CTCL lawsuits: the records that matter now that MDL 3180 is moving
A plain-English update on Dupixent CTCL lawsuits in MDL 3180 and the records families should gather for review.
-
Dupixent CTCL MDL 3180: Build the Timeline Before Records Get Hard to Find
The Dupixent CTCL MDL is underway in New Jersey. Families should preserve prescription, dermatology, pathology, and oncology records now.
-
Dupixent CTCL MDL 3180: What the Transfer Order Means for Patients
What patients and families should know after Dupixent CTCL claims were centralized in MDL No. 3180 in New Jersey.
-
Boston Scientific SCS MDL 3181: A July 2026 Checklist for Patients
A plain-English July 2026 update on Boston Scientific spinal cord stimulator MDL 3181, including shocks, burns, lead migration, revision surgery, and records to gather.
-
Depo-Provera MDL 3140: the July 27 conference is a reminder not to wait on records
A practical update on Depo-Provera MDL 3140, the July 27 conference, Rule 702 schedule, and records potential meningioma claimants should gather now.
-
Depo-Provera MDL 3140: what to gather before the July 27 hearing
Depo-Provera meningioma claims are moving quickly. Here are the records to gather before the July 27 hearing and any final settlement process.
-
Depo-Provera MDL 3140 Update: Settlement Talk Does Not End the Work for Meningioma Claimants
A July 2026 plain-English update on Depo-Provera meningioma lawsuits, the federal MDL, settlement-in-principle reports, label history, and records potential claimants should save now.
-
Roblox MDL 3166 update: what parents should know about the federal child safety cases
A careful July 2026 update for families following the Roblox child safety MDL, including case status, allegations, and practical record-preservation steps.
-
Tavneos Liver Injury Update: FDA Withdrawal Push and What Patients Should Know
FDA regulators are pursuing withdrawal of Tavneos approval after serious liver injury reports. Here is what patients and families should know in July 2026.
